ADVANCED PHAGE THERAPIES
We harness our technology to deliver novel microbiome-focused phage
therapeies to alleviate conditions such as IBD, cancer, and skin disorders.
BX001 is a topical gel of a phage cocktail comprised of natural phage capable of modulating P. acnes, in acne prone skin. Acne is the most common skin condition in the United States, affecting up to 50 million people of all ages. For most people, acne diminishes over time and tends to disappear or decrease by age 25. However, some individuals continue to suffer from acne well into their 30s, 40s and later. The market for acne therapies in the US and 5 largest EU countries was estimated to reach over $2.8 billion in 2018.
BX001 main attributes are as follows:
- Active on antibiotic resistant P. acnes strains
- Penetrates biofilm
- Does not affect other bacteria besides P. acnes
- Self-amplifying – 50-100 phage produced from each bacteria eradicated
Manufacturing and formulation activities are underway. Clinical trials are expected to initiate H4 2019.
BX002 offers a groundbreaking approach for treating IBD as it targets a possible underlying cause for the disease, whereas existing medications offer only symptomatic relief to this chronic, lifelong condition. BiomX plans to file an IND application with the US FDA for BX002 in 2019. Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, affect as many as 1.6 million Americans, most of whom are diagnosed before age 35. Medications today offer symptomatic relief to these chronic, lifelong conditions, but do not cure them. IBD can significantly affect a patient’s quality of life and may have a high financial burden. The global IBD market is valued at over $8 billion.
Harnessing Synthetic Biology